The Psychedelics as Medicine Report: Fourth Edition
The flagship report has been expanded to include market intelligence on adult-use frameworks in addition to psychedelics as medicine. Insights from business leaders, regulators and researchers empower investors to identify emerging opportunities.
Psychedelic Medicines
Milestones in psychedelic medicine
Ketamine
MDMA
Psilocybin
LSD
Psychedelic Research
Clinical trials
Scientific papers of note
Accessing psilocybin in the UK
Intellectual Property
Patents in psychedelic medicine
Market Sizing
Ketamine-assisted therapy
Psilocybin-assisted therapy
MDMA-assisted therapy
Adult-use programmes
Regulatory Frameworks
Oregon Psilocybin Services
Innovative Licensing and Access Pathway
Healthcare Providers
Therapist training programmes
Expert Contributors
Dr Laura Squire OBE - Chief Healthcare Quality and Access Officer, MHRA
Dr Ben Sessa - Head of Psychedelic Medicine, Awakn Life Sciences
Angela Allbee MPA - Oregon Psilocybin Services, Oregon Health Authority
Crispin Blunt MP - Chair at Conservative Drug Policy Reform Group
Dr Neil Maresky - Chief Executive Officer, Psyence Group
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Subscribe to the Psychedelics Newsletter
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.